Treatment outcome in performance status 2 advanced NSCLC patients administered platinum-based combination chemotherapy

Nina Helbekkmo; Ulf Aasebø; Stein H Sundstrøm; Christian von Plessen; Paal Fr Brunsvig; Roy M Bremnes; Norwegian Lung Cancer Study Group

doi:10.1016/j.lungcan.2008.03.003

Treatment outcome in performance status 2 advanced NSCLC patients administered platinum-based combination chemotherapy

Nina Helbekkmo, Ulf Aasebø, Stein H Sundstrøm, Christian von Plessen, Paal Fr Brunsvig, Roy M Bremnes, Norwegian Lung Cancer Study Group

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Abstrakt

BACKGROUND: There is no consensus regarding chemotherapy to patients with advanced NSCLC (ANSCLC) and performance status (PS) 2. Using data from a national multicenter study comparing two third-generation carboplatin-based regimens in ANSCLC patients, we evaluated the outcome of PS 2 patients.

PATIENTS AND METHODS: The 123 PS 2 patients were compared to 309 PS 0/1 patients regarding survival, quality of life (QOL) and treatment toxicity.

RESULTS: PS 2 patients had lower haemoglobin, lower global QOL and more pain, nausea/vomiting and dyspnea at inclusion. 68% of PS 2 patients received three chemotherapy courses vs. 85% in the PS 0/1 group (P<0.01). Median and 1-year survival were lower in the PS 2 group, 4.5 vs. 8.9 months and 10% vs. 37% (P<.01). More PS 2 patients needed blood transfusions (P=0.03) and hospitalization (P<0.01). In contrast, PS 2 patients had better relief of pain and dyspnea, and tended to a better global QOL and did not experience more leucopoenia, infections or bleeding.

CONCLUSIONS: Despite shorter survival, treatment toxicity was acceptable and PS 2 patients achieved better improvement of pain and dyspnea and tended to better global QOL when compared to PS 0/1 patients.

Originalsprog	Engelsk
Tidsskrift	Lung cancer (Amsterdam, Netherlands)
Vol/bind	62
Udgave nummer	2
Sider (fra-til)	253-60
Antal sider	8
ISSN	0169-5002
DOI	https://doi.org/10.1016/j.lungcan.2008.03.003
Status	Udgivet - nov. 2008

Emneord

Antineoplastic Combined Chemotherapy Protocols
Carboplatin
Carcinoma, Non-Small-Cell Lung
Deoxycytidine
Humans
Kaplan-Meier Estimate
Karnofsky Performance Status
Lung Neoplasms
Quality of Life
Treatment Outcome
Vinblastine

Dokumenter og links

10.1016/j.lungcan.2008.03.003

Fingeraftryk Dyk ned i forskningsemnerne om 'Treatment outcome in performance status 2 advanced NSCLC patients administered platinum-based combination chemotherapy'. Sammen danner de et unikt fingeraftryk.

Citationsformater

@article{7a5912e578c0490d8d6daf674283d981,

title = "Treatment outcome in performance status 2 advanced NSCLC patients administered platinum-based combination chemotherapy",

abstract = "BACKGROUND: There is no consensus regarding chemotherapy to patients with advanced NSCLC (ANSCLC) and performance status (PS) 2. Using data from a national multicenter study comparing two third-generation carboplatin-based regimens in ANSCLC patients, we evaluated the outcome of PS 2 patients.PATIENTS AND METHODS: The 123 PS 2 patients were compared to 309 PS 0/1 patients regarding survival, quality of life (QOL) and treatment toxicity.RESULTS: PS 2 patients had lower haemoglobin, lower global QOL and more pain, nausea/vomiting and dyspnea at inclusion. 68% of PS 2 patients received three chemotherapy courses vs. 85% in the PS 0/1 group (P<0.01). Median and 1-year survival were lower in the PS 2 group, 4.5 vs. 8.9 months and 10% vs. 37% (P<.01). More PS 2 patients needed blood transfusions (P=0.03) and hospitalization (P<0.01). In contrast, PS 2 patients had better relief of pain and dyspnea, and tended to a better global QOL and did not experience more leucopoenia, infections or bleeding.CONCLUSIONS: Despite shorter survival, treatment toxicity was acceptable and PS 2 patients achieved better improvement of pain and dyspnea and tended to better global QOL when compared to PS 0/1 patients.",

keywords = "Antineoplastic Combined Chemotherapy Protocols, Carboplatin, Carcinoma, Non-Small-Cell Lung, Deoxycytidine, Humans, Kaplan-Meier Estimate, Karnofsky Performance Status, Lung Neoplasms, Quality of Life, Treatment Outcome, Vinblastine",

author = "Nina Helbekkmo and Ulf Aaseb{\o} and Sundstr{\o}m, {Stein H} and {von Plessen}, Christian and Brunsvig, {Paal Fr} and Bremnes, {Roy M} and {Norwegian Lung Cancer Study Group}",

year = "2008",

month = nov,

doi = "10.1016/j.lungcan.2008.03.003",

language = "English",

volume = "62",

pages = "253--60",

journal = "Lung Cancer",

issn = "0169-5002",

publisher = "Elsevier",

number = "2",

}

Treatment outcome in performance status 2 advanced NSCLC patients administered platinum-based combination chemotherapy. / Helbekkmo, Nina; Aasebø, Ulf; Sundstrøm, Stein H; von Plessen, Christian; Brunsvig, Paal Fr; Bremnes, Roy M; Norwegian Lung Cancer Study Group.

I: Lung cancer (Amsterdam, Netherlands), Bind 62, Nr. 2, 11.2008, s. 253-60.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

TY - JOUR

T1 - Treatment outcome in performance status 2 advanced NSCLC patients administered platinum-based combination chemotherapy

AU - Helbekkmo, Nina

AU - Aasebø, Ulf

AU - Sundstrøm, Stein H

AU - von Plessen, Christian

AU - Brunsvig, Paal Fr

AU - Bremnes, Roy M

AU - Norwegian Lung Cancer Study Group

PY - 2008/11

Y1 - 2008/11

N2 - BACKGROUND: There is no consensus regarding chemotherapy to patients with advanced NSCLC (ANSCLC) and performance status (PS) 2. Using data from a national multicenter study comparing two third-generation carboplatin-based regimens in ANSCLC patients, we evaluated the outcome of PS 2 patients.PATIENTS AND METHODS: The 123 PS 2 patients were compared to 309 PS 0/1 patients regarding survival, quality of life (QOL) and treatment toxicity.RESULTS: PS 2 patients had lower haemoglobin, lower global QOL and more pain, nausea/vomiting and dyspnea at inclusion. 68% of PS 2 patients received three chemotherapy courses vs. 85% in the PS 0/1 group (P<0.01). Median and 1-year survival were lower in the PS 2 group, 4.5 vs. 8.9 months and 10% vs. 37% (P<.01). More PS 2 patients needed blood transfusions (P=0.03) and hospitalization (P<0.01). In contrast, PS 2 patients had better relief of pain and dyspnea, and tended to a better global QOL and did not experience more leucopoenia, infections or bleeding.CONCLUSIONS: Despite shorter survival, treatment toxicity was acceptable and PS 2 patients achieved better improvement of pain and dyspnea and tended to better global QOL when compared to PS 0/1 patients.

AB - BACKGROUND: There is no consensus regarding chemotherapy to patients with advanced NSCLC (ANSCLC) and performance status (PS) 2. Using data from a national multicenter study comparing two third-generation carboplatin-based regimens in ANSCLC patients, we evaluated the outcome of PS 2 patients.PATIENTS AND METHODS: The 123 PS 2 patients were compared to 309 PS 0/1 patients regarding survival, quality of life (QOL) and treatment toxicity.RESULTS: PS 2 patients had lower haemoglobin, lower global QOL and more pain, nausea/vomiting and dyspnea at inclusion. 68% of PS 2 patients received three chemotherapy courses vs. 85% in the PS 0/1 group (P<0.01). Median and 1-year survival were lower in the PS 2 group, 4.5 vs. 8.9 months and 10% vs. 37% (P<.01). More PS 2 patients needed blood transfusions (P=0.03) and hospitalization (P<0.01). In contrast, PS 2 patients had better relief of pain and dyspnea, and tended to a better global QOL and did not experience more leucopoenia, infections or bleeding.CONCLUSIONS: Despite shorter survival, treatment toxicity was acceptable and PS 2 patients achieved better improvement of pain and dyspnea and tended to better global QOL when compared to PS 0/1 patients.

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Carboplatin

KW - Carcinoma, Non-Small-Cell Lung

KW - Deoxycytidine

KW - Humans

KW - Kaplan-Meier Estimate

KW - Karnofsky Performance Status

KW - Lung Neoplasms

KW - Quality of Life

KW - Treatment Outcome

KW - Vinblastine

U2 - 10.1016/j.lungcan.2008.03.003

DO - 10.1016/j.lungcan.2008.03.003

M3 - Journal article

C2 - 18417246

VL - 62

SP - 253

EP - 260

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 2

ER -